Closure of atrial septal defect and patent foramen ovale

Closing an atrial septal defect or a patent foramen ovale means shutting the opening between the two upper chambers of the heart, with a catheter-delivered implant or by surgery. MeSH describes a septal occluder device as a catheter-delivered implant used for closing abnormal holes in the cardiovascular system, especially heart septal defects. A 2023 open-access review says transcatheter device closure is the preferred way of closing septum secundum defects and that careful patient selection and follow-up are necessary. A 2026 review says the indications, timing and long-term safety of patent foramen ovale closure remain controversial.

Also called PFO closure · ASD closure · Septal closure

  • Intervention
  • In this atlas

Overview

Technical summary

MeSH descriptor D055989, Septal Occluder Device (broad, because the descriptor names the implant and not the procedure). Its scope note describes a catheter-delivered implant used for closing abnormal holes in the cardiovascular system, especially heart septal defects. MedlinePlus lists cardiac catheterization to repair simple defects, such as a small hole in the inside wall of the heart, among the treatments for congenital heart defects. A 2023 open-access narrative review of closure devices for atrial septal defect (Cureus, CC BY 3.0) says transcatheter device closure is the preferred way of closing septum secundum defects; that a meta-analysis found the transcatheter approach had a high success rate and lower rates of adverse events and shorter hospital stays than surgery; and that complications are relatively rare. A 2026 open-access review of patent foramen ovale (MedComm, CC BY 4.0) says transcatheter closure has evolved into a secondary prevention strategy for patients with a PFO-related stroke, that apart from three randomized trials in stroke secondary prevention no other randomized trial has yielded encouraging results, and that long-term surveillance for arrhythmias and residual shunts is still needed. These are the reviews' statements; the atlas gives no rule about who should have an opening closed, by which route, or what medicine follows, and records no trial figures. The US approval of one device for secundum atrial septal defect is on that product's own page.

About this intervention

Type
Procedure
Mechanism
A catheter-delivered implant, carried by a thin tube guided through a vein into the heart, closes the opening (MeSH scope note; MedlinePlus).

Classification codes

  • MeSH MeSH linked-data descriptor record fetched on 2026-11-18, lastUpdated 2010-01-01; the record states no yearly MeSH release D055989

Claims and evidence

Context People having a patent foramen ovale closed (2026 review)

Recipient
Recipient not specified
Population
People with a patent foramen ovale whose closure is considered, mainly after a PFO-related stroke, as the review describes them.
Care setting
Not stated for the review as a whole. The review discusses the closure procedure and its follow-up.
Geography
Not stated for the review as a whole.
Life stage
Not restricted. The review lists elderly people, children, pregnant women and athletes as groups in whom diagnostic and predictive tools need further investigation; this record makes no statement about them.
Gestational age
Not reported
Postnatal age
Not reported
Follow-up
Not applicable (a narrative review; follow-up periods of individual studies are not recorded).
Eligibility: 2 inclusion criteria; exclusion criteria not stated
Included
  • Having a patent foramen ovale
  • Being considered for closure of a patent foramen ovale
Excluded
None stated
  • Description Evidence synthesis Certainty not assessed

    A 2026 open-access review of patent foramen ovale (MedComm) says transcatheter closure has evolved into a secondary prevention strategy for patients with a PFO-related stroke, and that substantial evidence has established transcatheter closure for secondary prevention in patients with cryptogenic stroke. It says the indications, timing and long-term safety of closure remain controversial, that long-term surveillance for complications such as arrhythmias and residual shunts is still needed, and that apart from three randomized trials in stroke secondary prevention no other randomized trial has yielded encouraging results for closure.

    Applies to Recipient not specified People having a patent foramen ovale closed (2026 review)

    Certainty method
    Not assessed
    Limitations
    A narrative review; the statements come from its abstract, introduction and conclusions, which cite the trials without giving figures here. The review uses the abbreviation CS for cryptogenic stroke. Trial figures, device types and patient-selection criteria are not repeated, and the atlas states no rule about who should have a patent foramen ovale closed.
    Last checked
    2026-11-18
    Next evidence check due
    Not scheduled
    Sources and citations (5)
    1. Supports Patent Foramen Ovale: Epidemiology, Risk Factors, Pathophysiology, Clinical Features, Diagnosis, and Management

      Publication · MedComm · Edition PMC Open Access subset full-text XML, from NCBI E-utilities (MedComm 2026), fetched 2026-11-18. A narrative review. Used for how common a patent foramen ovale is, the conditions linked with it, and what the review says about closure; diagnostic detail and device types are not used. · PMCID: PMC13547099 · PMID: 42707360 · DOI: 10.1002/mco2.70957

      Locator
      Introduction, para 2, sentence 4 (part)
      How it applies
      Transcatheter closure has evolved into a secondary prevention strategy for PFO-related stroke.
      Retrieved
      Source effective date
      Not reported
      Source state
      Current
      Version fingerprint
      f0b4ebb513263ec28c3efbbd9df9af28be224756753838bc1b172e0e6fb2a096
      Reuse basis
      PMC Open Access subset article under the Creative Commons Attribution licence (https://creativecommons.org/licenses/by/4.0/, content-type ccbylicense, CC BY 4.0). The article's own license element states the licence. The XML is committed unaltered, with the citation and licence kept in the file. The raw file is committed in the atlas repository.
    2. Supports Patent Foramen Ovale: Epidemiology, Risk Factors, Pathophysiology, Clinical Features, Diagnosis, and Management

      Publication · MedComm · Edition PMC Open Access subset full-text XML, from NCBI E-utilities (MedComm 2026), fetched 2026-11-18. A narrative review. Used for how common a patent foramen ovale is, the conditions linked with it, and what the review says about closure; diagnostic detail and device types are not used. · PMCID: PMC13547099 · PMID: 42707360 · DOI: 10.1002/mco2.70957

      Locator
      Conclusions and Perspectives, para 1, sentence 3
      How it applies
      Substantial evidence has established closure for secondary prevention in cryptogenic stroke.
      Retrieved
      Source effective date
      Not reported
      Source state
      Current
      Version fingerprint
      f0b4ebb513263ec28c3efbbd9df9af28be224756753838bc1b172e0e6fb2a096
      Reuse basis
      PMC Open Access subset article under the Creative Commons Attribution licence (https://creativecommons.org/licenses/by/4.0/, content-type ccbylicense, CC BY 4.0). The article's own license element states the licence. The XML is committed unaltered, with the citation and licence kept in the file. The raw file is committed in the atlas repository.
    3. Supports Patent Foramen Ovale: Epidemiology, Risk Factors, Pathophysiology, Clinical Features, Diagnosis, and Management

      Publication · MedComm · Edition PMC Open Access subset full-text XML, from NCBI E-utilities (MedComm 2026), fetched 2026-11-18. A narrative review. Used for how common a patent foramen ovale is, the conditions linked with it, and what the review says about closure; diagnostic detail and device types are not used. · PMCID: PMC13547099 · PMID: 42707360 · DOI: 10.1002/mco2.70957

      Locator
      Abstract, para 1, sentence 3 (end)
      How it applies
      Indications, timing and long-term safety remain controversial.
      Retrieved
      Source effective date
      Not reported
      Source state
      Current
      Version fingerprint
      f0b4ebb513263ec28c3efbbd9df9af28be224756753838bc1b172e0e6fb2a096
      Reuse basis
      PMC Open Access subset article under the Creative Commons Attribution licence (https://creativecommons.org/licenses/by/4.0/, content-type ccbylicense, CC BY 4.0). The article's own license element states the licence. The XML is committed unaltered, with the citation and licence kept in the file. The raw file is committed in the atlas repository.
    4. Supports Patent Foramen Ovale: Epidemiology, Risk Factors, Pathophysiology, Clinical Features, Diagnosis, and Management

      Publication · MedComm · Edition PMC Open Access subset full-text XML, from NCBI E-utilities (MedComm 2026), fetched 2026-11-18. A narrative review. Used for how common a patent foramen ovale is, the conditions linked with it, and what the review says about closure; diagnostic detail and device types are not used. · PMCID: PMC13547099 · PMID: 42707360 · DOI: 10.1002/mco2.70957

      Locator
      Conclusions and Perspectives, para 2, sentence 4 (end)
      How it applies
      Long-term surveillance for complications such as arrhythmias and residual shunts is still needed.
      Retrieved
      Source effective date
      Not reported
      Source state
      Current
      Version fingerprint
      f0b4ebb513263ec28c3efbbd9df9af28be224756753838bc1b172e0e6fb2a096
      Reuse basis
      PMC Open Access subset article under the Creative Commons Attribution licence (https://creativecommons.org/licenses/by/4.0/, content-type ccbylicense, CC BY 4.0). The article's own license element states the licence. The XML is committed unaltered, with the citation and licence kept in the file. The raw file is committed in the atlas repository.
    5. Supports Patent Foramen Ovale: Epidemiology, Risk Factors, Pathophysiology, Clinical Features, Diagnosis, and Management

      Publication · MedComm · Edition PMC Open Access subset full-text XML, from NCBI E-utilities (MedComm 2026), fetched 2026-11-18. A narrative review. Used for how common a patent foramen ovale is, the conditions linked with it, and what the review says about closure; diagnostic detail and device types are not used. · PMCID: PMC13547099 · PMID: 42707360 · DOI: 10.1002/mco2.70957

      Locator
      Conclusions and Perspectives, para 3, sentence 1
      How it applies
      Apart from three trials in stroke secondary prevention, no other randomized trial has yielded encouraging results.
      Retrieved
      Source effective date
      Not reported
      Source state
      Current
      Version fingerprint
      f0b4ebb513263ec28c3efbbd9df9af28be224756753838bc1b172e0e6fb2a096
      Reuse basis
      PMC Open Access subset article under the Creative Commons Attribution licence (https://creativecommons.org/licenses/by/4.0/, content-type ccbylicense, CC BY 4.0). The article's own license element states the licence. The XML is committed unaltered, with the citation and licence kept in the file. The raw file is committed in the atlas repository.

Context People having an atrial septal defect closed (2023 device review)

Recipient
Recipient not specified
Population
People whose atrial septal defect is closed through a catheter, as the review describes them. It also covers some patients with a patent foramen ovale, and the comparison with surgery.
Care setting
Catheterization laboratory, as the review describes the procedure. Surgery is mentioned only as a comparison.
Geography
The review discusses United States device approvals; this record does not use them.
Life stage
Not restricted in the abstract or introduction. The review includes studies of adults and of children; this record makes no statement about newborns, pregnancy or any age group.
Gestational age
Not reported
Postnatal age
Not reported
Follow-up
Not applicable (a narrative review; follow-up periods of individual studies are not recorded).
Eligibility: 1 inclusion criterion; exclusion criteria not stated
Included
  • Having an atrial septal defect that is closed through a catheter
Excluded
None stated
  • Description Evidence synthesis Certainty not assessed

    A 2023 open-access narrative review of devices for transcatheter closure of atrial septal defect (Cureus) says transcatheter device closure is the preferred way of closing septum secundum defects. It says a meta-analysis found the transcatheter approach had a high success rate, lower rates of adverse events and shorter hospital stays compared with surgery, that complications have been reported but are relatively rare, and that careful patient selection and follow-up are necessary to minimize complications and ensure optimal outcomes. MedlinePlus lists cardiac catheterization to repair simple defects, such as a small hole in the inside wall of the heart, among the treatments for congenital heart defects.

    Applies to Recipient not specified People having an atrial septal defect closed (2023 device review)

    Certainty method
    Not assessed
    Limitations
    A narrative review of devices, written in 2023; the outcome statements come from studies it cites, and its device list and trial figures are not repeated. The review mentions surgical closure only in comparison. The atlas states no rule about who should have a defect closed or by which route; the MedlinePlus sentence is general patient information.
    Last checked
    2026-11-18
    Next evidence check due
    Not scheduled
    Sources and citations (8)
    1. Supports Transcatheter Closure of Atrial Septal Defect: A Review of Currently Used Devices

      Publication · Cureus · Edition PMC Open Access subset full-text XML, from NCBI E-utilities (Cureus 2023), fetched 2026-11-18. A narrative review. Used for what the review says about transcatheter closure of atrial septal defects; the device list and trial figures are not used. · PMCID: PMC10329454 · PMID: 37425612 · DOI: 10.7759/cureus.40132

      Locator
      Introduction and background, para 1, sentence 9 (first part)
      How it applies
      Transcatheter device closure is the preferred way to close septum secundum defects.
      Retrieved
      Source effective date
      Not reported
      Source state
      Current
      Version fingerprint
      53c591583671de4cfe5e457b41f5d738ca323fdfed42568cf7b0c1dd76feec64
      Reuse basis
      PMC Open Access subset article under the Creative Commons Attribution licence (https://creativecommons.org/licenses/by/3.0/, content-type ccbylicense, CC BY 3.0). The article's own license element states the licence. The XML is committed unaltered, with the citation and licence kept in the file. The raw file is committed in the atlas repository.
    2. Supports Transcatheter Closure of Atrial Septal Defect: A Review of Currently Used Devices

      Publication · Cureus · Edition PMC Open Access subset full-text XML, from NCBI E-utilities (Cureus 2023), fetched 2026-11-18. A narrative review. Used for what the review says about transcatheter closure of atrial septal defects; the device list and trial figures are not used. · PMCID: PMC10329454 · PMID: 37425612 · DOI: 10.7759/cureus.40132

      Locator
      Abstract, para 1, sentence 15 (first part)
      How it applies
      A meta-analysis found the transcatheter approach had a high success rate.
      Retrieved
      Source effective date
      Not reported
      Source state
      Current
      Version fingerprint
      53c591583671de4cfe5e457b41f5d738ca323fdfed42568cf7b0c1dd76feec64
      Reuse basis
      PMC Open Access subset article under the Creative Commons Attribution licence (https://creativecommons.org/licenses/by/3.0/, content-type ccbylicense, CC BY 3.0). The article's own license element states the licence. The XML is committed unaltered, with the citation and licence kept in the file. The raw file is committed in the atlas repository.
    3. Supports Transcatheter Closure of Atrial Septal Defect: A Review of Currently Used Devices

      Publication · Cureus · Edition PMC Open Access subset full-text XML, from NCBI E-utilities (Cureus 2023), fetched 2026-11-18. A narrative review. Used for what the review says about transcatheter closure of atrial septal defects; the device list and trial figures are not used. · PMCID: PMC10329454 · PMID: 37425612 · DOI: 10.7759/cureus.40132

      Locator
      Abstract, para 1, sentence 15 (end)
      How it applies
      Lower rates of adverse events and shorter hospital stays than surgery.
      Retrieved
      Source effective date
      Not reported
      Source state
      Current
      Version fingerprint
      53c591583671de4cfe5e457b41f5d738ca323fdfed42568cf7b0c1dd76feec64
      Reuse basis
      PMC Open Access subset article under the Creative Commons Attribution licence (https://creativecommons.org/licenses/by/3.0/, content-type ccbylicense, CC BY 3.0). The article's own license element states the licence. The XML is committed unaltered, with the citation and licence kept in the file. The raw file is committed in the atlas repository.
    4. Supports Transcatheter Closure of Atrial Septal Defect: A Review of Currently Used Devices

      Publication · Cureus · Edition PMC Open Access subset full-text XML, from NCBI E-utilities (Cureus 2023), fetched 2026-11-18. A narrative review. Used for what the review says about transcatheter closure of atrial septal defects; the device list and trial figures are not used. · PMCID: PMC10329454 · PMID: 37425612 · DOI: 10.7759/cureus.40132

      Locator
      Abstract, para 1, sentence 16 (first part)
      How it applies
      Complications of transcatheter closure have been reported.
      Retrieved
      Source effective date
      Not reported
      Source state
      Current
      Version fingerprint
      53c591583671de4cfe5e457b41f5d738ca323fdfed42568cf7b0c1dd76feec64
      Reuse basis
      PMC Open Access subset article under the Creative Commons Attribution licence (https://creativecommons.org/licenses/by/3.0/, content-type ccbylicense, CC BY 3.0). The article's own license element states the licence. The XML is committed unaltered, with the citation and licence kept in the file. The raw file is committed in the atlas repository.
    5. Supports Transcatheter Closure of Atrial Septal Defect: A Review of Currently Used Devices

      Publication · Cureus · Edition PMC Open Access subset full-text XML, from NCBI E-utilities (Cureus 2023), fetched 2026-11-18. A narrative review. Used for what the review says about transcatheter closure of atrial septal defects; the device list and trial figures are not used. · PMCID: PMC10329454 · PMID: 37425612 · DOI: 10.7759/cureus.40132

      Locator
      Abstract, para 1, sentence 17
      How it applies
      Complications are relatively rare.
      Retrieved
      Source effective date
      Not reported
      Source state
      Current
      Version fingerprint
      53c591583671de4cfe5e457b41f5d738ca323fdfed42568cf7b0c1dd76feec64
      Reuse basis
      PMC Open Access subset article under the Creative Commons Attribution licence (https://creativecommons.org/licenses/by/3.0/, content-type ccbylicense, CC BY 3.0). The article's own license element states the licence. The XML is committed unaltered, with the citation and licence kept in the file. The raw file is committed in the atlas repository.
    6. Supports Transcatheter Closure of Atrial Septal Defect: A Review of Currently Used Devices

      Publication · Cureus · Edition PMC Open Access subset full-text XML, from NCBI E-utilities (Cureus 2023), fetched 2026-11-18. A narrative review. Used for what the review says about transcatheter closure of atrial septal defects; the device list and trial figures are not used. · PMCID: PMC10329454 · PMID: 37425612 · DOI: 10.7759/cureus.40132

      Locator
      Abstract, para 1, sentence 20
      How it applies
      Careful patient selection and follow-up are necessary.
      Retrieved
      Source effective date
      Not reported
      Source state
      Current
      Version fingerprint
      53c591583671de4cfe5e457b41f5d738ca323fdfed42568cf7b0c1dd76feec64
      Reuse basis
      PMC Open Access subset article under the Creative Commons Attribution licence (https://creativecommons.org/licenses/by/3.0/, content-type ccbylicense, CC BY 3.0). The article's own license element states the licence. The XML is committed unaltered, with the citation and licence kept in the file. The raw file is committed in the atlas repository.
    7. Supports Congenital Heart Defects (MedlinePlus health topic)

      Webpage · U.S. National Library of Medicine (MedlinePlus) · Edition Page fetched 2026-10-14. The page shows a last-updated date in its footer; it is not used here.

      Locator
      Summary, What are the treatments for congenital heart defects?
      How it applies
      MedlinePlus: cardiac catheterization to repair simple defects.
      Retrieved
      Source effective date
      Not reported
      Source state
      Current
      Version fingerprint
      8a8235db9024c57a4d94c6eca43f79959079f4a59cadc7bbe15b9e7e583f480d
      Reuse basis
      MedlinePlus says works produced by the federal government are not copyrighted and that its summaries on health topic pages are in the public domain, and asks users to acknowledge MedlinePlus as the source (MedlinePlus using-content page, fetched 2026-10-14, hash only). Some images on MedlinePlus are copyrighted; this atlas uses none. The raw page is committed in the atlas repository. Terms re-checked on 2026-11-08 at https://medlineplus.gov/about/using/usingcontent/ (page not committed; sha256 0825c88f5bd1dade7c8693bad8035b0d1f25fd0b8c5053e488c618fb2b62e722). That page says health topic page summaries, medical test information and Genetics page summaries are in the public domain, and that A.D.A.M. Medical Encyclopedia content (medlineplus.gov/ency/), ASHP drug monographs and most images are copyrighted. This source is a public-domain page, not an A.D.A.M. page, so public text stays quote; any A.D.A.M. page would be cite_only.
    8. Background MeSH scope note for descriptor D055989 (Septal Occluder Device)

      Dataset · U.S. National Library of Medicine · Edition MeSH linked-data record of the preferred concept M0524981 of descriptor D055989, fetched 2026-11-18. The scope note is on this concept record, not on the descriptor record. · MeSH: M0524981

      Locator
      scopeNote.@value, sentence 1 (first part)
      How it applies
      MeSH scope note for a septal occluder device.
      Retrieved
      Source effective date
      Not reported
      Source state
      Current
      Version fingerprint
      0bf9f56e8a4655464b7574c149341ac7e89f41d00cf0fa2f804e89c01d274f37
      Reuse basis
      The NLM web policies page (sha256 c8b7026b5c3fcfd1b0cb88755077f6a99a5f2159eecd42b0e7d1a5ad9b30ec55, hash only) says works produced by the U.S. government are not subject to copyright protection in the United States and asks users to acknowledge NLM as the source. The NLM MeSH terms and conditions page (sha256 f33b14141a5b6c8a2b1464c751dbdbb0a0d476c913851bf2a8c3d5c14b1afce7, hash only) asks redistributors to maintain current data or to make known that their copy may not reflect the most current data. This copy was fetched on 2026-11-18 and may not reflect the most current data. The raw bytes are committed in the atlas repository.

Clinical links

Each link reports what one cited claim says about one population. "Evaluated for" means studied, not shown to work. These links do not show that anything is effective or right for you.

Record details

Record id
cardio:closure-of-pfo-and-asd
Content hash
0282e2149425c7be527744bb38787576a955e48f5c47edfc636b21264b6dd37e